IL2 and neoplasm: In the initial clinical study demonstrating the curative potential of TIL-ACT, 29 metastatic melanoma patients were treated with autologous TILs accompanied by high-dose interleukin-2 (IL-2), with a 31% objective response rate (ORR, complete response (CR) + partial response (PR)), and four patients achieving complete tumor regression [9].